Abstract
Navitoclax, which is a type of senolytic drug, selectively eliminates senescent cells. This study aimed to evaluate the therapeutic potential of navitoclax in treatment of angiotensin II (Ang II)-induced heart failure in mice. Navitoclax or vehicle was administrated in mice with Ang II-induced heart failure. Cardiac function and electrophysiology were assessed before and after administration of navitoclax. Cardiac remodeling, including morphological changes, fibrosis, and inflammatory responses, was analyzed in myocardial tissue. Cellular effects of navitoclax were validated in isolated primary cardiomyocytes and cardiac fibroblasts in vitro. Echocardiography of mice showed that navitoclax improved cardiac dysfunction by improving the left ventricular ejection fraction (vehicle: 45.88 ± 2.19%; navitoclax: 54.70 ± 1.65%, P < 0.01). In cardiac electrophysiological testing, navitoclax increased conduction velocity (vehicle: 1.37 ± 0.05 mm/ms; navitoclax: 1.69 ± 0.08 mm/ms, P < 0.05) and decreased susceptibility to ventricular tachyarrhythmia induced by programmed electrical stimulation. Histopathological staining, immunofluorescence, and western blotting examinations showed that navitoclax ameliorated Ang II-induced cardiac fibros...Continue Reading
References
Mar 15, 2000·Journal of the American College of Cardiology·J N CohnN Sharpe
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Dec 2, 2008·Nature·Thomas ThumStefan Engelhardt
Jul 3, 2010·EMBO Molecular Medicine·Ariela BenigniGiuseppe Remuzzi
Nov 24, 2011·Heart Failure Clinics·James B Strait, Edward G Lakatta
Apr 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charles M RudinLeena Gandhi
Dec 5, 2012·Nature Reviews. Cardiology·Karl T WeberIvan C Gerling
Jan 10, 2013·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Patrick T O'GaraUNKNOWN Society for Cardiovascular Angiography and Interventions
Feb 23, 2013·European Journal of Heart Failure·Valentina LazzariniChristopher M O'Connor
Mar 5, 2013·The Journal of Clinical Investigation·Tamara TchkoniaJames L Kirkland
Nov 5, 2013·Journal of Molecular and Cellular Cardiology·Thao P NguyenJames N Weiss
Nov 5, 2013·Circulation Research·Mohamed Ameen IsmahilSumanth D Prabhu
May 23, 2014·Nature·Jan M van Deursen
Dec 15, 2015·Nature Medicine·Jianhui ChangDaohong Zhou
Jan 5, 2016·European Journal of Heart Failure·Evelien E S van RietFrans H Rutten
Jan 13, 2016·Comprehensive Physiology·Edit Tanai, Stefan Frantz
May 10, 2017·International Journal of Radiation Oncology, Biology, Physics·Jin PanAimin Meng
Jul 22, 2017·Nature Reviews. Drug Discovery·Bennett G ChildsJan M van Deursen
Dec 15, 2017·Science Translational Medicine·David LagaresAndrew M Tager
Jun 6, 2018·Hypertension·Linda CambierEduardo Marbán
Jun 7, 2018·Physiological Reviews·Steven J ForresterSatoru Eguchi
Feb 10, 2019·The EMBO Journal·Rhys AndersonJoão F Passos
Mar 29, 2019·Aging Cell·Anna WalaszczykGavin D Richardson
Aug 10, 2019·Journal of the American College of Cardiology·Filippos TriposkiadisJaved Butler
Citations
Feb 14, 2021·Cancers·Valerie J CarpenterDavid A Gewirtz
Apr 2, 2021·International Journal of Cardiology·Ampadu O JacksonShiyin Long
May 28, 2021·Circulation Research·Joel G RurikJonathan A Epstein
Jun 13, 2021·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Wolfgang MerktDavid Lagares
May 9, 2021·Cardiovascular Research·Maggie S ChenJessica C Garbern
Nov 10, 2021·Clinical Science·Jeffrey KingsleySatoru Eguchi